Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00849290 · ClinicalTrials.gov registry record · Phase 2

Immunotherapy For Men With Objective Disease Progression On Protocol D9902 Part B (NCT00065442)

A Phase 2 study, sponsored by Dendreon.

Completed
Registry status
Phase 2
Development phase
113
Enrollment target

NCT00849290: Completed Phase 2 study, sponsored by Dendreon.

NCT00849290 is a Phase 2 study that has completed, run by Dendreon. The registered enrollment target is 113 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (15% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00849290, a Phase 2 study, has completed, sponsored by Dendreon.

COMPLETED
Registry status
Phase 2
Development phase
113 participants
Enrollment target

Study Summary

This is an open label, Phase 2 trial of APC8015F immunotherapy in men with objective disease progression on protocol D9902 part B (NCT00065442)

Primary Outcome

All subjects who received at least one infusion of APC8015F (N = 109) were included in the safety analysis set and were followed for safety. Refer to Serious Adverse Events and Other Adverse Events.

Interventions

  • BIOLOGICAL APC8015F

Trial Details

FieldValue
Enrollment Target 113 participants
Start Date 2004-04
Est. Completion 2009-04
Phase Phase 2
Dendreon

18 total trials

What the finished NCT00849290 record still lists

NCT00849290 is an interventional study that assigns participants to a tested intervention. The registered 113 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (15% lower).

The record links to 0 conditions, and to 1 intervention - of which APC8015F is the first listed.

NCT00849290 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00849290 about?

NCT00849290 is a clinical study titled "Immunotherapy For Men With Objective Disease Progression On Protocol D9902 Part B (NCT00065442)". This is an open label, Phase 2 trial of APC8015F immunotherapy in men with objective disease progression on protocol D9902 part B (NCT00065442)

What is the current status of trial NCT00849290?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 113 participants. The study started on 2004-04. Estimated completion is 2009-04.

What interventions are being tested in trial NCT00849290?

The interventions under investigation include: APC8015F (BIOLOGICAL).

Who is sponsoring clinical trial NCT00849290?

This trial is sponsored by Dendreon, which has 18 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00849290's enrollment target sits among peer trials

113 631st of 2000 higher than 1,370 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00748254 · 113 participants

    Laser-based Photoacoustic Tomography of Human Inflammatory Arthritis

  • NCT04753190 · 113 participants · NA

    Light Timing Study

  • NCT05799248 · 113 participants · Phase 3

    Role of rhPSMA-7.3 PET/CT Imaging in Men With High-Risk Prostate Cancer Following Conventional Imaging and Associated Changes in Medical Management

  • NCT07216105 · 113 participants · Phase 1

    FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00849290, the US trial registry maintained by the National Library of Medicine. NCT00849290 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.